Study of Satraplatin (JM-216) in Combination With Docetaxel
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, non-randomized, Phase I dose finding study of the
investigational, oral cytotoxic drug, satraplatin (JM-216), in combination with docetaxel in
patients with advanced solid tumors for whom curative therapy is not available. Please refer
to the Eligibility Criteria below for key inclusion and exclusion criteria.
PURPOSE: The purpose of this trial is to determine a tolerable dose and schedule for the
combination of satraplatin and docetaxel when given to patients with advanced solid tumors.
WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member
of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically
proven to be one of the most effective classes of anticancer therapies. Unlike the currently
marketed platinum-based drugs, satraplatin can be given orally.